Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers
摘要:
A series of dihydrobenzoxathiin SERAMs with alkylated pyrrolidine side chains or alkylated linkers was prepared. Minor modifications in the side chain or linker resulted in significant effects on biological activity, especially in uterine tissue.
3- Or 4-monosubstituted phenol derivatives useful as H3 ligands
申请人:Warner-Lambert Company LLC
公开号:EP1593679A1
公开(公告)日:2005-11-09
The invention relates to 3- or 4-monosubstituted phenol derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
The invention relates to 5,6 - dihydropyrrolo [2,1-a] isoquinoline and pyrrolo[2,1-a] isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.
2,2,6,6-Tetramethylpiperidin-1-yloxycarbonyl: A Protecting Group for Primary, Secondary, and Heterocyclic Amines
作者:Joseph R. Lizza、Maximilian Bremerich、Stephanie R. McCabe、Peter Wipf
DOI:10.1021/acs.orglett.8b02874
日期:2018.11.2
n-1-yloxycarbonyl (Tempoc) protectinggroup is readily introduced by the reaction of amines with a new acyl transfer reagent, 4-nitrophenyl (2,2,6,6-tetramethylpiperidin-1-yl) carbonate (NPTC). Tempoc has a reactivity profile that complements the commonly used t-butyloxycarbonyl (Boc) and benzyloxycarbonyl (Cbz) protectinggroups. Deprotection can be achieved under mild reductive conditions with in
[EN] INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL<br/>[FR] INHIBITION DU CANAL IONIQUE À POTENTIEL DE RÉCEPTEUR TRANSITOIRE A1
申请人:HYDRA BIOSCIENCES INC
公开号:WO2015164643A1
公开(公告)日:2015-10-29
The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential Al ion channel (TRPA1).
The present invention relates to the use of novel compounds of formula I:
wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.